Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BridgeBio Pharma, Inc.
  6. Summary
    BBIO   US10806X1028

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
63.74(c) 62.47(c) 63.18(c) 62.63(c) 61.33 Last
1 105 950 826 520 1 676 360 2 229 610 2 194 115 Volume
-0.30% -1.99% +1.14% -0.87% -2.08% Change
More quotes
Financials (USD)
Sales 2021 69,4 M - -
Net income 2021 -562 M - -
Net Debt 2021 368 M - -
P/E ratio 2021 -15,3x
Yield 2021 -
Sales 2022 101 M - -
Net income 2022 -609 M - -
Net Debt 2022 576 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Capitalization 9 156 M 9 156 M -
EV / Sales 2021 137x
EV / Sales 2022 95,9x
Nbr of Employees 391
Free-Float 65,1%
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Read more
Sector
Pharmaceuticals
Calendar
06/17 | 12:00pmShareholder meeting
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
06/14BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(..
GL
06/01BRIDGEBIO PHARMA  : Corporate Presentation June 2021
PU
06/01BRIDGEBIO PHARMA  : Obtains FDA Fast Track Designation for Hypoparathyroidism Tr..
MT
06/01BRIDGEBIO PHARMA, INC.  : Other Events (form 8-K)
AQ
06/01BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Tr..
GL
06/01BRIDGEBIO PHARMA  : Affiliate QED Therapeutics and Partner Helsinn Group Announc..
BU
05/31BRIDGEBIO PHARMA  : Affiliate QED Therapeutics and Partner Helsinn Group Announc..
AQ
05/28BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Annou..
GL
05/25BRIDGEBIO PHARMA  : Corporate Presentation May 2021
PU
05/21BRIDGEBIO PHARMA  : UBS Starts BridgeBio Pharma at Buy with $80 Price Target
MT
05/14BRIDGEBIO PHARMA, INC.  : Results of Operations and Financial Condition, Financi..
AQ
05/14BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(..
GL
05/14BRIDGEBIO PHARMA  : Gene Therapy Receives US FDA's Fast Track Designation
MT
05/14BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene..
GL
05/11BRIDGEBIO PHARMA, INC.  : Other Events (form 8-K)
AQ
More news
News in other languages on BRIDGEBIO PHARMA, INC.

- No features available -

More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Analysis
KKR earnings surge 63% on strong capital market business
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 81,10 $
Last Close Price 61,33 $
Spread / Highest target 48,4%
Spread / Average Target 32,2%
Spread / Lowest Target 15,8%
EPS Revisions
Managers and Directors
NameTitle
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
BRIDGEBIO PHARMA, INC.-11.93%9 350
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939